A new human genotype prone to variant Creutzfeldt Jakob disease

British Medical Journal

Volumn 332, Issue 7551, 2006, Pages 1164-1165

  Wilson, Kumanan ^a   Ricketts, Maura N ^b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PRION PROTEIN; VALINE;

BLOOD DONOR; CREUTZFELDT JAKOB DISEASE; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; EDITORIAL; EPIDEMIC; GENETIC PREDISPOSITION; GENOTYPE; HEALTH CARE POLICY; HETEROZYGOTE; HUMAN; IATROGENIC DISEASE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; GENETICS; NOTE;

CREUTZFELDT-JAKOB SYNDROME; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS;

EID: 33646925414     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.332.7551.1164     Document Type: Editorial

References (12)

1. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996;347:921-5.
2. Ghani AC, Ferguson NM, Donnelly CA, Anderson RM. Predicted vCJD mortality in Great Britain. Nature 2000;406:583-4.
3. Ironside JW, Bishop MT, Connolly K, Hegazy D, Lowrie S, Grice ML, et al. Variant Creutzfeldt-Jakob disease: prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study. BMJ 2006;332:1186-8.
4. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004;364:527-9.
5. Bishop M, Hart P, Aitchison L, Baybutt H, Plinston C, Thomson V, et al. Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurology 2006;5:393-398.
6. Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie J, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004;363:417-21.
7. Wilson K, Code C, Ricketts MN. Risk of acquiring Creutzfeldt-Jakob disease from blood transfusions: systematic review of case-control studies. BMJ 2000;321:17-9.
8. Brown P, Preece M, Brandel JP, Sato T, McShane L, Zerr I, et al. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 2000;55:1075-81.
9. Wilson K, Ricketts MN. The success of precaution? Managing the risk of transfusion transmission of variant Creutzfeldt-Jakob disease. Transfusion 2004;44:1475-8.
10. Fichet G, Comoy E, Duval C, Antloga K, Dehen C, Charbonnier A, et al. Novel methods for disinfection of prion-contaminated medical devices. Lancet 2004;364:521-6.
11. Sowemimo-Coker S, Kascsak R, Kim A, Andrade F, Pesci S, Kascsak R, et al. Removal of exogenous (spiked) and endogenous prion infectivity from red cells with a new prototype of leukoreduction filter. Transfusion 2005;45:1839-44.
12. McCullough J, Anderson D, Brookie D, Bouchard JP, Fergusson D, Joly J, et al. Consensus conference on vCJD screening of blood donors: report of the panel. Transfusion 2004;44:675-83.